| Identification | Back Directory | [Name]
ARG-LYS-GLU-VAL-TYR ACETATE SALT | [CAS]
105184-37-0 | [Synonyms]
SP-5 ACETATE SALT
Splenopentin diacetate
SPLENOPENTIN ACETATE SALT
ARG-LYS-GLU-VAL-TYR ACETATE
SP-5, Splenin Fragment 32-36
ARG-LYS-GLU-VAL-TYR ACETATE SALT
SPLENIN FRAGMENT 32-36 ACETATE SALT
ARG-LYS-GLU-VAL-TYR ACETATE SALT USP/EP/BP
SP-5, Splenin Fragment 32-36, Splenopentin
L-Arginyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-tyrosine diacetate
L-Tyrosine,N-[N-[N-(N2-L-arginyl-L-lysyl)-L-α-glutamyl]-L-valyl]-,diacetate (salt)
4-[[6-amino-2-[[2-amino-5-(diaminomethylideneamino)-1-oxopentyl]amino]-1-oxohexyl]amino]-5-[[1-[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic a | [Molecular Formula]
C33H55N9O11 | [MDL Number]
MFCD00133108 | [MOL File]
105184-37-0.mol | [Molecular Weight]
753.84 |
| Hazard Information | Back Directory | [Uses]
Splenopentin diacetate is a synthetic immunomodulating pentapeptide corresponding to the residues 32-36 of the splenic hormone splenin. Splenopentin diacetate influences both early T and B cell differentiation, to increase the number of antibody-forming cells in mice after gamma irradiation[1][2]. | [Biological Activity]
Splenopentin diacetate is a synthetic immunomodulatory pentapeptide corresponding to residues 32-36 of the spleen hormone spleen protein. It affects early T and B cell differentiation, thereby increasing the number of antibody-forming cells in gamma-irradiated mice. | [in vitro]
Splenopentin (1-100 μM) augments human NK cells and has no cytotoxicity.
Splenopentin (0.1 ng/mL-10 μg/mL; 3 h) induces phenotypic differentiation of both T- and B -cell precursor cells.
| [in vivo]
Splenopentin (1 mg/kg; ip three times a week for 7-90 d) accelerates Langerhans cell recruitment and leads to pretreatment levels of Langerhans cell (LC) density in the skin of mice.
Splenopentin (0.01-100 μg per mouse; ip) has no demonstrable effect on neuromuscular transmission of mice. | Animal Model: | Female Balb /c/Bln mice were injected Cyclophosphamide or Dexamethasone for 5 consecutive days | | Dosage: | 1 mg /kg | | Administration: | Ip three times a week for 7-90 days | | Result: | Reached the normal number of epidermal LCs at 28 days after the beginning of Cyclophosphamide treatment.
Accelerated restoration process and reached the normal LC density in the skin after 70 days in Dexamethasone treatment grops. | | [References]
[1] Singh VK, et, al. Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res. 1998;17(3):345-68. DOI:10.1007/BF02786456
[2] Rastogi A, et, al. Augmentation of human natural killer cells by splenopentin analogs. FEBS Lett. 1993 Feb 8;317(1-2):93-5. DOI:10.1016/0014-5793(93)81498-o
[3] Audhya T, et, al. Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc Natl Acad Sci U S A. 1984 May;81(9):2847-9. DOI:10.1073/pnas.81.9.2847
[4] Gruner S, et, al. Stimulation of the recruitment of epidermal Langerhans cells by splenopentin. Arch Dermatol Res. 1990;281(8):526-9. DOI:10.1007/BF00412738 |
|
|